Pioneering Platform Advancing the Field of MRD
Performance to drive progress, results to revolutionize healthcare. Learn why Bio-Rad is the digital PCR market leader through customer case studies.
Tumor Response to Therapy Research:
Neo-adjuvant therapy is often employed to shrink tumors prior to curative treatment efforts. Molecular responses to cancer therapy as measured by ctDNA indicates effect earlier than standard methods, widening the treatment window, allowing a physician to switch to a more effective drug in the case of poor or no response to initial therapy. ddPCR technology is an ultra-sensitive method that can detect molecular responses earlier and more precisely than other commonly adopted molecular technologies.
Analyzing MRD levels is vital to both indicating achievement of a deep molecular response (remission) in response to oncological therapy as well as potential reoccurrence of cancer (relapse). MRD testing has become widely adopted for monitoring hematological malignancies and is now being implemented for solid tumor diseases. Because disease markers are often in very low abundance in the blood, especially for solid tumors, ddPCR technology is ideal to implement for MRD monitoring given its unmatched sensitivity, precision, and absolute quantitation capabilities.
Droplet Digital PCR Technology in the Field
ctDNA Analysis Powered by ddPCR™ Technology
Learn how ddPCR plays a critical role in lung cancer sample analysis at Biodesix
The Power of ddPCR Analysis for Lung Cancer Research
Dr. Schuuring discusses how the high sensitivity and absolution quantification capabilities of ddPCR are advancing the field of ctDNA analysis
Expanding ctDNA Analysis Power with the QX600 Droplet Digital PCR System
Dr. Dobrovic and Dr. Wong, highlight the advantages of ddPCR for liquid biopsy analysis and how multiplexing with the QX600 ddPCR System has streamlined their efforts
More about ddPCR in MRD
Concordance between Droplet Digital PCR and Next-Generation Sequencing in Measuring Allele Frequency for Genomic Reference Materials
Examine data concordance between ddPCR and NGS when analyzing reference materials with target allele frequencies between 0.1% - 10%. Download the White Paper Now!
Learn more about the promise of ctDNA analysis for the field of oncology and how some experts are using it today. Download the White Paper Now!
Sign Up to Be the First to Know
Receive ddPCR Technology and MRD Updates
Sign up to be notified when new ddPCR technology and MRD related resources like tips and tricks, posters, protocols and webinars become available.